Drug intelligence / Profile preview

influenza HA vaccine

Development stage: Approved
Lead developer: Research Foundation for Microbial Diseases of Osaka University
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

**Biken HA** is a Japan-marketed seasonal influenza hemagglutinin vaccine produced by the Research Foundation for Microbial Diseases of Osaka University. It is an inactivated influenza vaccine containing viral hemagglutinin antigens selected for the relevant influenza season and is administered by subcutaneous injection to prevent influenza. The product was used as the active-comparator injectable vaccine in NCT02955030, a Phase 1 study of Nitto Denko's sublingual influenza-vaccine candidate NSV0001. ([biken.or.jp](https://www.biken.or.jp/medical/products/detail/2505))

Brand names: Biken HA
Other names: Influenza HA Vaccine BIKENビケンHA

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on influenza HA vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on influenza HA vaccine.

Explore the full profile